A Phase II Study on Continuous Infusional Paclitaxel and 5-Fu as First-line Chemotherapy for Patients with Advanced Esophageal Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Phase II Study on Continuous Infusional Paclitaxel and 5-Fu as First-line Chemotherapy for Patients with Advanced Esophageal Cancer

Published:2012-11-30 Issue:11 Volume:13 Page:5587-5591
ISSN:1513-7368
Container-title:Asian Pacific Journal of Cancer Prevention
language:en
Short-container-title:Asian Pacific Journal of Cancer Prevention

Author:

Gu Ming,Li Su-Yi,Huang Xin-En,Lin Yan,Cheng Hong-Yan,Liu Lin

Publisher

Asian Pacific Organization for Cancer Prevention

Subject

Cancer Research,Public Health, Environmental and Occupational Health,Oncology,Epidemiology

Link

http://ocean.kisti.re.kr/downfile/crosscheck/apocp/JAKO201206735656369.pdf

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Luteolin attenuates cancer cell stemness in PTX-resistant oesophageal cancer cells through mediating SOX2 protein stability;Pharmacological Research;2021-12

2. Concurrent liposomal paclitaxel and cisplatin chemotherapy improved outcomes for locally advanced esophageal squamous cell carcinoma treated with intensity-modulated radiotherapy;Annals of Translational Medicine;2019-07

3. Single-cell Transcriptome Analyses Reveal Molecular Signals to Intrinsic and Acquired Paclitaxel Resistance in Esophageal Squamous Cancer Cells;Cancer Letters;2018-04

4. Oesophageal cancer: Which treatment is the easiest to swallow? A review of combined modality treatments for resectable carcinomas;Critical Reviews in Oncology/Hematology;2017-05

5. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma;Oncotarget;2016-11-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3